Korean J Physiol Pharmacol.  2011 Dec;15(6):363-369. 10.4196/kjpp.2011.15.6.363.

Inhibition of Inducible Nitric Oxide Synthase Attenuates Monosodium Urate-induced Inflammation in Mice

• Ju TJ
• Dan JM
• Cho YJ
• Park SY

• KMID: 2285423
• DOI: http://doi.org/10.4196/kjpp.2011.15.6.363

Abstract

The present study elucidated the effect of the selective inducible nitric oxide synthase (iNOS) inhibitor N6-(1-iminoethyl)-L-lysine (L-NIL) on monosodium urate (MSU) crystal-induced inflammation and edema in mice feet. L-NIL (5 or 10 mg/kg/day) was administered intraperitoneally 4 h before injection of MSU (4 mg) into the soles of mice hindlimb feet. Twenty-four hours after MSU injection, foot thickness was increased by 160% and L-NIL pretreatment reduced food pad swelling in a dose dependent manner. Pretreatment of 10 mg/kg/day L-NIL significantly suppressed the foot pad swelling by MSU. Plasma level of nitric oxide (NO) metabolites and gene expression and protein level of iNOS in feet were increased by MSU, which was suppressed by L-NIL pretreatment. Similar pattern of change was observed in nitrotyrosine level. MSU increased the gene expression of tumor necrosis factor (TNF)-alpha and interleukin (IL)-1beta and L-NIL pretreatment suppressed MSU-induced cytokines expression. The mRNA levels of superoxide dismutase and glutathione peroxidase1 were increased by MSU and L-NIL pretreatment normalized the gene expression. Phosphorylation of extracellular signal-regulated kinase 1/2 and p38 was increased by MSU, which was suppressed by L-NIL pretreatment. The mRNA levels of iNOS, TNF-alpha, and IL-1beta were increased by MSU in human dermal fibroblasts, C2C12 myoblasts, and human fetal osteoblasts in vitro, which was attenuated by L-NIL in a dose dependent manner. This study shows that L-NIL inhibits MSU-induced inflammation and edema in mice feet suggesting that iNOS might be involved in MSU-induced inflammation.

Keyword

Uric acid; Gout; iNOS

MeSH Terms

Animals
Cytokines
Edema
Fibroblasts
Foot
Gene Expression
Glutathione
Gout
Hindlimb
Humans
Inflammation
Interleukins
Mice
Myoblasts
Nitric Oxide
Nitric Oxide Synthase Type II
Osteoblasts
Phosphorylation
Phosphotransferases
Plasma
RNA, Messenger
Superoxide Dismutase
Tumor Necrosis Factor-alpha
Tyrosine
Uric Acid
Cytokines
Glutathione
Interleukins
Nitric Oxide
Nitric Oxide Synthase Type II
Phosphotransferases
RNA, Messenger
Superoxide Dismutase
Tumor Necrosis Factor-alpha
Tyrosine
Uric Acid

Figure

• 

  Fig. 1 Thickness of feet in mice injected with monosodium-urate (MSU) into hindlimb feet sole. N6-(1-iminoethyl)-L-lysine (L-NIL; 5 and 10 mg/kg) was injected intraperitoneally 4 h before MSU (4 mg) injection. Data is presented as mean±SE. Experimental cases are seven in each group. *p<0.05 vs. Saline, #p<0.05 vs. MSU.

• 

  Fig. 2 Nitric oxide metabolites in plasma (A) and the expression of inducible nitric oxide synthase (iNOS; B, C) and nitrotyrosine (D) in the feet of mice injected with monosodium-urate (MSU) into hindlimb sole. N6-(1-iminoethyl)-L-lysine (L-NIL; 10 mg/kg) was injected intraperitoneally 4 h before MSU (4 mg) injection. Data is presented as mean±SE. Experimental cases are seven in each group. *p<0.05 vs. Saline, #p<0.05 vs. MSU.

• 

  Fig. 3 The mRNA level of inflammatory cytokines and antioxidant enzymes in the foot of mice injected with monosodium-urate (MSU) into hindlimb sole. N6-(1-iminoethyl)-Llysine (L-NIL; 10 mg/kg) was injected intraperitoneally 4 h before MSU (4 mg) injection. Interleukin (IL)-1β (A); tumor necrosis factor (TNF)-α (B); glutathione peroxidase (GPx) 1 (C); superoxide dismutase (SOD) (D). Data is presented as mean±SE. Experimental cases are seven in each group. *p<0.05 vs. Saline, #p<0.05 vs. MSU.

• 

  Fig. 4 The phosphorylation of extracellular signal-related kinase (ERK) 1/2 (A) and p38 (B) in the foot of mice injected with monosodium-urate (MSU) into hindlimb sole. N6-(1-iminoethyl)-L-lysine (L-NIL; 10 mg/kg) was injected intraperitoneally 4 h before MSU (4 mg) injection. Data is presented as mean±SE. Experimental cases are seven in each group. *p<0.05 vs. Saline, #p<0.05 vs. MSU.

• 

  Fig. 5 The mRNA level of iNOS, tumor necrosis factor (TNF)-α, and interleukin (IL)-1β in human dermal fibroblast (HDF; A~C), C2C12 myoblast, and (D~F) human fetal osteoblast (hFOB)1.19 (G~I). The cells were treated with 2 mg/ml monosodium-urate (MSU) for 2 h. N6-(1-iminoethyl)-L-lysine (L-NIL) was treated into cells 30 min before MSU treatment. Data is presented as mean±SE of three separate experiments. *p<0.05 vs. Control, #p<0.05 vs. MSU, &p<0.05 vs. 0.25 mg/ml L-NIL.

Reference

1. Keith MP, Gilliland WR. Updates in the management of gout. Am J Med. 2007; 120:221–224. PMID: 17349440.

2. Sabina EP, Rasool M, Mathew L, Ezilrani P, Indu H. 6-Shogaol inhibits monosodium urate crystal-induced inflammation--an in vivo and in vitro study. Food Chem Toxicol. 2010; 48:229–235. PMID: 19819286.

3. Eggebeen AT. Gout: an update. Am Fam Physician. 2007; 76:801–808. PMID: 17910294.

4. Di Giovine FS, Malawista SE, Nuki G, Duff GW. Interleukin 1 (IL 1) as a mediator of crystal arthritis. Stimulation of T cell and synovial fibroblast mitogenesis by urate crystal-induced IL 1. J Immunol. 1987; 138:3213–3218. PMID: 3033070.

5. Sabina EP, Chandal S, Rasool MK. Inhibition of monosodium urate crystal-induced inflammation by withaferin A. J Pharm Pharm Sci. 2008; 11:46–55. PMID: 19183513.

6. Michel T, Feron O. Nitric oxide synthases: which, where, how, and why? J Clin Invest. 1997; 100:2146–2152. PMID: 9410890.

7. Noronha BT, Li JM, Wheatcroft SB, Shah AM, Kearney MT. Inducible nitric oxide synthase has divergent effects on vascular and metabolic function in obesity. Diabetes. 2005; 54:1082–1089. PMID: 15793247.

8. Tsuchiya K, Sakai H, Suzuki N, Iwashima F, Yoshimoto T, Shichiri M, Hirata Y. Chronic blockade of nitric oxide synthesis reduces adiposity and improves insulin resistance in high fat-induced obese mice. Endocrinology. 2007; 148:4548–4556. PMID: 17584959.

9. Kelm M. Nitric oxide metabolism and breakdown. Biochim Biophys Acta. 1999; 1411:273–289. PMID: 10320663.

10. Torres SH, De Sanctis JB, de L Briceño M, Hernández N, Finol HJ. Inflammation and nitric oxide production in skeletal muscle of type 2 diabetic patients. J Endocrinol. 2004; 181:419–427. PMID: 15171690.

11. Beckman JS, Koppenol WH. Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol. 1996; 271:C1424–C1437. PMID: 8944624.

12. Cha HN, Kim YW, Kim JY, Kim YD, Song IH, Min KN, Park SY. Lack of inducible nitric oxide synthase does not prevent aging-associated insulin resistance. Exp Gerontol. 2010; 45:711–718. PMID: 20493940.

13. Chen L, Hsieh MS, Ho HC, Liu YH, Chou DT, Tsai SH. Stimulation of inducible nitric oxide synthase by monosodium urate crystals in macrophages and expression of iNOS in gouty arthritis. Nitric Oxide. 2004; 11:228–236. PMID: 15566969.

14. Liu R, Lioté F, Rose DM, Merz D, Terkeltaub R. Proline-rich tyrosine kinase 2 and Src kinase signaling transduce monosodium urate crystal-induced nitric oxide production and matrix metalloproteinase 3 expression in chondrocytes. Arthritis Rheum. 2004; 50:247–258. PMID: 14730623.

15. Sabina EP, Rasool M. An in vivo and in vitro potential of Indian ayurvedic herbal formulation Triphala on experimental gouty arthritis in mice. Vascul Pharmacol. 2008; 48:14–20. PMID: 18065272.

16. Becker MA, Schumacher HR Jr, Wortmann RL, MacDonald PA, Eustace D, Palo WA, Streit J, Joseph-Ridge N. Febuxostat compared with allopurinol in patients with hyperuricemia and gout. N Engl J Med. 2005; 353:2450–2461. PMID: 16339094.

17. Connor JR, Manning PT, Settle SL, Moore WM, Jerome GM, Webber RK, Tjoeng FS, Currie MG. Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. Eur J Pharmacol. 1995; 273:15–24. PMID: 7537678.

18. Chicoine LG, Tzeng E, Bryan R, Saenz S, Paffett ML, Jones J, Lyons CR, Resta TC, Nelin LD, Walker BR. Intratracheal adenoviral-mediated delivery of iNOS decreases pulmonary vasoconstrictor responses in rats. J Appl Physiol. 2004; 97:1814–1822. PMID: 15258125.

19. Cha HN, Hong GR, Kim YW, Kim JY, Dan JM, Park SY. Deficiency of iNOS Does Not Prevent Isoproterenol-induced Cardiac Hypertrophy in Mice. Korean J Physiol Pharmacol. 2009; 13:153–159. PMID: 19885031.

20. van't Hof RJ, Hocking L, Wright PK, Ralston SH. Nitric oxide is a mediator of apoptosis in the rheumatoid joint. Rheumatology (Oxford). 2000; 39:1004–1008. PMID: 10986306.

21. Mäki-Petäjä KM, Cheriyan J, Booth AD, Hall FC, Brown J, Wallace SM, Ashby MJ, McEniery CM, Wilkinson IB. Inducible nitric oxide synthase activity is increased in patients with rheumatoid arthritis and contributes to endothelial dysfunction. Int J Cardiol. 2008; 129:399–405. PMID: 18571252.

22. Grabowski PS, Wright PK, Van't Hof RJ, Helfrich MH, Ohshima H, Ralston SH. Immunolocalization of inducible nitric oxide synthase in synovium and cartilage in rheumatoid arthritis and osteoarthritis. Br J Rheumatol. 1997; 36:651–655. PMID: 9236674.

23. Heale CE, Fåhraeus-Van Ree GE, Rahman P, Richardson VJ. Progressive and concordant expression of PKC-eta and iNOS phenotypes in monocytes from patients with rheumatoid arthritis: association with disease severity. J Histochem Cytochem. 2007; 55:495–503. PMID: 17242466.

24. Borderie D, Hilliquin P, Hernvann A, Kahan A, Menkes CJ, Ekindjian OG. Nitric oxide synthase is expressed in the lymphomononuclear cells of synovial fluid in patients with rheumatoid arthritis. J Rheumatol. 1999; 26:2083–2088. PMID: 10529121.

25. Vuolteenaho K, Moilanen T, Hämäläinen M, Moilanen E. Regulation of nitric oxide production in osteoarthritic and rheumatoid cartilage. Role of endogenous IL-1 inhibitors. Scand J Rheumatol. 2003; 32:19–24. PMID: 12635941.

26. Järvinen K, Vuolteenaho K, Nieminen R, Moilanen T, Knowles RG, Moilanen E. Selective iNOS inhibitor 1400W enhances anti-catabolic IL-10 and reduces destructive MMP-10 in OA cartilage. Survey of the effects of 1400W on inflammatory mediators produced by OA cartilage as detected by protein antibody array. Clin Exp Rheumatol. 2008; 26:275–282. PMID: 18565249.

27. Cuzzocrea S, Chatterjee PK, Mazzon E, McDonald MC, Dugo L, Di Paola R, Serraino I, Britti D, Caputi AP, Thiemermann C. Beneficial effects of GW274150, a novel, potent and selective inhibitor of iNOS activity, in a rodent model of collagen-induced arthritis. Eur J Pharmacol. 2002; 453:119–129. PMID: 12393067.

28. Jaramillo M, Naccache PH, Olivier M. Monosodium urate crystals synergize with IFN-gamma to generate macrophage nitric oxide: involvement of extracellular signal-regulated kinase 1/2 and NF-kappa B. J Immunol. 2004; 172:5734–5742. PMID: 15100320.

29. Liu R, O'Connell M, Johnson K, Pritzker K, Mackman N, Terkeltaub R. Extracellular signal-regulated kinase 1/extracellular signal-regulated kinase 2 mitogen-activated protein kinase signaling and activation of activator protein 1 and nuclear factor kappaB transcription factors play central roles in interleukin-8 expression stimulated by monosodium urate monohydrate and calcium pyrophosphate crystals in monocytic cells. Arthritis Rheum. 2000; 43:1145–1155. PMID: 10817569.

30. Liu W, Kato M, Itoigawa M, Murakami H, Yajima M, Wu J, Ishikawa N, Nakashima I. Distinct involvement of NF-kappaB and p38 mitogen-activated protein kinase pathways in serum deprivation-mediated stimulation of inducible nitric oxide synthase and its inhibition by 4-hydroxynonenal. J Cell Biochem. 2001; 83:271–280. PMID: 11573244.

31. Liu-Bryan R, Lioté F. Monosodium urate and calcium pyrophosphate dihydrate (CPPD) crystals, inflammation, and cellular signaling. Joint Bone Spine. 2005; 72:295–302. PMID: 15990350.

32. Kanellis J, Watanabe S, Li JH, Kang DH, Li P, Nakagawa T, Wamsley A, Sheikh-Hamad D, Lan HY, Feng L, Johnson RJ. Uric acid stimulates monocyte chemoattractant protein-1 production in vascular smooth muscle cells via mitogen-activated protein kinase and cyclooxygenase-2. Hypertension. 2003; 41:1287–1293. PMID: 12743010.

33. Inokuchi T, Ka T, Yamamoto A, Moriwaki Y, Takahashi S, Tsutsumi Z, Tamada D, Yamamoto T. Effects of ethanol on monosodium urate crystal-induced inflammation. Cytokine. 2008; 42:198–204. PMID: 18282764.

34. McInnes IB, Leung BP, Field M, Wei XQ, Huang FP, Sturrock RD, Kinninmonth A, Weidner J, Mumford R, Liew FY. Production of nitric oxide in the synovial membrane of rheumatoid and osteoarthritis patients. J Exp Med. 1996; 184:1519–1524. PMID: 8879223.

35. di Giovine FS, Malawista SE, Thornton E, Duff GW. Urate crystals stimulate production of tumor necrosis factor alpha from human blood monocytes and synovial cells. Cytokine mRNA and protein kinetics, and cellular distribution. J Clin Invest. 1991; 87:1375–1381. PMID: 2010550.

36. Chapman PT, Yarwood H, Harrison AA, Stocker CJ, Jamar F, Gundel RH, Peters AM, Haskard DO. Endothelial activation in monosodium urate monohydrate crystal-induced inflammation: in vitro and in vivo studies on the roles of tumor necrosis factor alpha and interleukin-1. Arthritis Rheum. 1997; 40:955–965. PMID: 9153559.

37. Rider TG, Jordan KM. The modern management of gout. Rheumatology (Oxford). 2010; 49:5–14. PMID: 19808695.

38. Chen YH, Hsieh SC, Chen WY, Li KJ, Wu CH, Wu PC, Tsai CY, Yu CL. Spontaneous resolution of acute gouty arthritis is associated with rapid induction of the anti-inflammatory factors TGFβ1, IL-10 and soluble TNF receptors and the intracellular cytokine negative regulators CIS and SOCS3. Ann Rheum Dis. 2011; 70:1655–1663. PMID: 21613312.

39. Ghio AJ, Kennedy TP, Rao G, Cooke CL, Miller MJ, Hoidal JR. Complexation of iron cation by sodium urate crystals and gouty inflammation. Arch Biochem Biophys. 1994; 313:215–221. PMID: 8080265.

40. Facchini FS. Near-iron deficiency-induced remission of gouty arthritis. Rheumatology (Oxford). 2003; 42:1550–1555. PMID: 12832712.